天新药业
(603235)
| 流通市值：43.81亿 | | | 总市值：130.41亿 |
| 流通股本：1.47亿 | | | 总股本：4.38亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,613,579,810.79 | 1,066,613,193.86 | 494,498,107.04 | 1,881,993,019.35 |
| 营业收入 | 1,613,579,810.79 | 1,066,613,193.86 | 494,498,107.04 | 1,881,993,019.35 |
| 二、营业总成本 | 1,058,098,256.39 | 671,166,795.68 | 329,541,762.38 | 1,360,268,236.63 |
| 营业成本 | 931,582,176.69 | 618,000,807.55 | 296,335,192.79 | 1,161,708,799.37 |
| 税金及附加 | 15,942,085.61 | 10,068,656.33 | 5,142,013.67 | 19,807,359.5 |
| 销售费用 | 24,631,752.99 | 17,043,652.05 | 3,088,016.52 | 32,864,170.55 |
| 管理费用 | 98,966,470.13 | 58,414,659.61 | 27,934,395.58 | 136,349,813.27 |
| 研发费用 | 72,715,184.45 | 45,045,430.51 | 22,774,738.56 | 111,964,592.3 |
| 财务费用 | -85,739,413.48 | -77,406,410.37 | -25,732,594.74 | -102,426,498.36 |
| 其中:利息费用 | - | 2,060,740.77 | - | 2,099,778.86 |
| 其中:利息收入 | - | 44,305,423.66 | 24,225,972.3 | 74,460,490.46 |
| 加:投资收益 | 3,650,670.48 | 364,869.03 | 364,869.03 | 2,074,607.89 |
| 资产处置收益 | 962.33 | - | - | - |
| 资产减值损失(新) | -5,231,148.92 | -5,231,148.92 | - | -12,363,832.71 |
| 信用减值损失(新) | -1,894,901.85 | -2,643,402.43 | -2,357,578.37 | 3,159,494.22 |
| 其他收益 | 35,733,010.74 | 23,961,148.05 | 13,402,766.59 | 47,623,073.35 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 587,740,147.18 | 411,897,863.91 | 176,366,401.91 | 562,218,125.47 |
| 加:营业外收入 | 41,460.68 | 31,985.75 | 14,019.71 | 6,045,173.71 |
| 减:营业外支出 | 2,797,593.87 | 1,866,086.93 | 644,101.44 | 3,093,769.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 584,984,013.99 | 410,063,762.73 | 175,736,320.18 | 565,169,529.97 |
| 减:所得税费用 | 90,501,036.02 | 64,895,301.29 | 28,187,315.85 | 89,316,231.33 |
| 六、净利润 | 494,482,977.97 | 345,168,461.44 | 147,549,004.33 | 475,853,298.64 |
| 持续经营净利润 | 494,482,977.97 | 345,168,461.44 | 147,549,004.33 | 475,853,298.64 |
| 归属于母公司股东的净利润 | 494,482,977.97 | 345,168,461.44 | 147,549,004.33 | 475,853,298.64 |
| (一)基本每股收益 | 1.13 | 0.79 | 0.34 | 1.09 |
| (二)稀释每股收益 | 1.13 | 0.79 | 0.34 | 1.09 |
| 九、综合收益总额 | 494,482,977.97 | 345,168,461.44 | 147,549,004.33 | 475,853,298.64 |
| 归属于母公司股东的综合收益总额 | 494,482,977.97 | 345,168,461.44 | 147,549,004.33 | 475,853,298.64 |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-30 | 2024-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |